Related Experiment Videos
Primary angioplasty for cardiogenic shock complicating acute myocardial infarction
R Calton1, T M Jaison, T David
1Department of Cardiology, Christian Medical College and Hospital, Ludhiana.
Insights
Primary percutaneous coronary angioplasty significantly reduces in-hospital mortality in acute myocardial infarction with cardiogenic shock compared to thrombolytic therapy. This aggressive invasive strategy offers better outcomes for high-risk cardiac patients.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Cardiogenic shock is a severe complication of acute myocardial infarction (AMI).
- Optimal reperfusion strategies for AMI complicated by cardiogenic shock remain a critical clinical question.
Purpose of the Study:
- To evaluate the effectiveness of primary percutaneous transluminal coronary angioplasty (PTCA) versus intravenous thrombolytic therapy (TLT) in patients with AMI and cardiogenic shock.
Main Methods:
- A study of 53 patients with AMI and cardiogenic shock, comparing primary PTCA (n=18) with TLT (n=35).
- Demographic data, risk factors, clinical presentation, angiographic results, and in-hospital mortality were analyzed.
- Angiographic success defined as <50% residual stenosis; TIMI flow grades assessed reperfusion.
Main Results:
- Primary PTCA group had a significantly lower in-hospital mortality rate (27.77%) compared to the TLT group (57.14%; p=0.04).
- Angiographic success was achieved in 78.94% of PTCA procedures, with TIMI III or II flow in 78.94% of treated vessels.
- In the TLT group, mortality was higher for patients presenting >6 hours from symptom onset (85.91%) versus <6 hours (50%).
Conclusions:
- Primary PTCA is associated with reduced in-hospital mortality in patients with AMI and cardiogenic shock.
- An aggressive invasive approach utilizing primary PTCA offers a survival benefit over TLT in this high-risk patient population.
Abstract:
To evaluate the role of primary percutaneous transluminal coronary angioplasty in cardiogenic shock, 53 patients admitted with the diagnosis of acute myocardial infarction and cardiogenic shock were studied. Thirty-five (66.0%) patients received intravenous thrombolytic therapy (streptokinase 15 lac units) and 18 (34.0%) underwent primary percutaneous transluminal coronary angioplasty. There was no significant difference in the mean age, risk factor profile, presence of prior myocardial infarction, site of myocardial infarction and cardiac enzyme levels at presentation between the two groups. More male patients were present in the group undergoing primary percutaneous transluminal coronary angioplasty (94.44% vs 68.57%; p = 0.04). The time delay between the onset of symptoms and presentation to the hospital did not differ significantly between the two groups (318.9 vs 320.0 minutes; p = NS). In the primary percutaneous transluminal coronary angioplasty group, 17 patients had a single infarct-related artery and one had both left anterior descending and right coronary artery occlusion. Thus in 18 patients, 19 vessels were attempted. Angiographic success (< 50% residual stenosis) was achieved in 15 (78.94%) vessels of which TIMI III flow was achieved in 10 (52.63%) vessels and TIMI II flow in five (26.31%). Intra-aortic balloon pump was needed in five (27.77%) patients undergoing coronary angioplasty. In-hospital mortality was 27.77 percent in patients undergoing primary percutaneous transluminal coronary angioplasty and 57.14 percent in patients receiving intravenous thrombolytic therapy (p = 0.04). In the thrombolytic therapy group, mortality was higher (85.91%) in patients presenting six hours or later after the onset of symptoms as compared to those presenting in less than six hours of the onset of symptoms (50%). In primary percutaneous transluminal coronary angioplasty group, mortality was 21.42 percent in patients with successful and 50 percent in patients with failed angioplasty. Thus, in patients with acute myocardial infarction and cardiogenic shock, an aggressive invasive strategy with primary percutaneous transluminal coronary angioplasty, as compared to intravenous thrombolytic therapy, is helpful in reducing in-hospital mortality.